Revenio Group (REG1V) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
29 Apr, 2026Executive summary
Q1 net sales reached EUR 27.3 million, up 4.8% year-over-year (8.4% currency-adjusted), with strong growth in the US and Europe, while APAC lagged due to tough comparables and currency headwinds.
Operating profit dropped 63.8% to EUR 2.4 million, impacted by EUR 3.1 million in one-off costs related to the Visionix acquisition and organizational changes.
Adjusted operating profit was EUR 5.8 million, down 12.2% year-over-year; adjusted operating profit margin was 21.3% of sales.
Cash flow from operations was negative at EUR -3.4 million, mainly due to increased accounts receivable and higher tax payments.
Visionix acquisition expands the addressable market from $1 billion to $2.5 billion, broadens the product portfolio, and is expected to accelerate growth and value creation.
Financial highlights
Gross margin decreased to 68.4% from 72.6% year-over-year, impacted by tariffs, FX headwinds, and product mix.
EBITDA declined 54.9% to EUR 3.5 million.
EPS dropped to EUR 0.092 from EUR 0.157 in Q1 2025.
Equity ratio remained high at 79.1%.
Net cash flow from operations at EUR -3.4 million.
Outlook and guidance
Previous financial guidance withdrawn due to the Visionix transaction; updated guidance to be provided post-completion.
Long-term targets include annual growth at 3x market rate and EBITDA margin of 25% for 2028–2029, approaching 30% beyond 2030.
EUR 20 million EBITDA uplift targeted by 2029, with 70% expected by 2027.
No dividend proposed for the financial year 2025.
Latest events from Revenio Group
- Merger forms a top global eye care leader, targeting EUR 20m+ synergies and rapid growth.REG1V
M&A announcement14 Apr 2026 - 2025 net sales up 6% to EUR 109.7M, with 2026 sales growth guided at 8–15% and margin recovery.REG1V
Q4 202511 Feb 2026 - Q2 net sales up 14.2%, strong cash flow, and 2024 sales growth guidance of 5–10%.REG1V
Q2 20242 Feb 2026 - Q3 net sales up 8.9%, operating profit down, AI diagnostics strengthened by Thirona Retina.REG1V
Q3 202417 Jan 2026 - Record Q1 sales and profit, broad-based growth, and strong outlook despite tariff risks.REG1V
Q1 202527 Dec 2025 - Record sales, robust cash flow, and 2025 guidance for up to 15% growth amid global risks.REG1V
Q4 202416 Dec 2025 - Strong sales and profit growth achieved despite currency and geopolitical challenges.REG1V
Q2 202523 Nov 2025 - Q3 2025 delivered strong sales and profit growth, with robust outlook and new product launches.REG1V
Q3 20254 Nov 2025